QurAlis

QurAlis wishes all a Happy Thanksgiving! May your Thanksgiving and year bring you abundance and joy. #grateful #thankful

QurAlis wishes all a Happy Thanksgiving! May your Thanksgiving and year bring you abundance and joy. #grateful #thankful

QurAlis is looking forward to the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024, in New York, NY. QurAlis’ CEO and co-founder, Kasper Roet, will present a corporate update on Wednesay, December 4, 2024 at 12:30pET. Management will also participate in one-on-one investor meetings. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/499B4hW

QurAlis is looking forward to the Piper Sandler 36th Annual Healthcare Conference being held December 3-5, 2024, in New York, NY. QurAlis’ CEO and co-founder, Kasper Roet, will present a corporate update on Wednesay, December 4, 2024 at 12:30pET. Management will also participate in one-on-one investor meetings. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/499B4hW

QurAlis Presents! QurAlis' CEO and co-founder Kasper Roet presented?at the Stifel Financial Corp. 2024 Healthcare Conference held last week in New York, NY. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases?

QurAlis Presents! QurAlis' CEO and co-founder Kasper Roet presented?at the Stifel Financial Corp. 2024 Healthcare Conference held last week in New York, NY. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases?

QurAlis Presents! QurAlis' chief technology officer Hagen Cramer, was a featured speaker at the TIDES: Oligonucleotides and Peptide Therapeutics Europe 2024 conference held last week in Hamburg, Germany. Hagen presented, "How to Prepare for a Successful IND/IMPD When Developing #Oligonucleotide Therapeutics," during the Oligonucleotide Chemistry, Manufacturing & Controls track which included (pictured l-to-r): Sergey Tsukanov, senior director, Chemistry, Eli Lilly & Co.; Hagen; Daniel Waschke, technical regulatory manager, F. Hoffmann-La Roche Ltd. (track chair); René Thürmer, deputy head BfArM Federal Institute for Drugs and Medical Devices; Tracey Burr, executive director, CMC Regulatory Affairs, Ionis; and Daniela Fischer, associate director, Regulatory Affairs CMC, Novartis Pharmaceutical Manufacturing (not pictured). #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/4fRaT1i

Yesterday we had our inspiring and energizing Inaugural Mind Matters Science Symposium, with support from Bayer.??? ?? Our speakers explored emerging treatments that target the underlying mechanisms of #neurodegeneration, addressed the unique challenges of clinical diversity, and examined the evolving landscape of funding for this research. Each session was designed to foster in-depth discussions, question prevailing ideas, and ignite creative thinking.? We then closed the day with a thought-provoking poster session. Congrats to our special winner Darby R. Schmidt of Violet Therapeutics. This event was another example of our commitment to fostering a community where #scientific, #academic, and #business expertise converge and we're grateful for everyone who came out to help make this mission possible! A special shoutout to our guest speakers: Prof. Dennis Selkoe, Li-Huei Tsai, Stephen Haggarty, Holly Massett, Tamiko MaGee-Rodgers, PhD, Dana Hilt, Andrea Machlitt, Serena Hung, Rhoda Au, Stefan Irion, Dan Elbaum, Christian Mirescu, Beth J Hoffman, Karen Bettauer Harris, Ricardo Dolmetsch, Huiyuan Zhang, and Stacie Weninger!

QurAlis Presents! QurAlis' chief technology officer Hagen Cramer, was a featured speaker at the TIDES: Oligonucleotides and Peptide Therapeutics Europe 2024 conference held last week in Hamburg, Germany. Hagen presented, "How to Prepare for a Successful IND/IMPD When Developing #Oligonucleotide Therapeutics," during the Oligonucleotide Chemistry, Manufacturing & Controls track which included (pictured l-to-r): Sergey Tsukanov, senior director, Chemistry, Eli Lilly & Co.; Hagen; Daniel Waschke, technical regulatory manager, F. Hoffmann-La Roche Ltd. (track chair); René Thürmer, deputy head BfArM Federal Institute for Drugs and Medical Devices; Tracey Burr, executive director, CMC Regulatory Affairs, Ionis; and Daniela Fischer, associate director, Regulatory Affairs CMC, Novartis Pharmaceutical Manufacturing (not pictured). #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/4fRaT1i

QurAlis is pleased to annouce that the Phase 1 ANQUR clinical trial evaluating QRL-201 for the treatment of #ALS has successfully completed the dose-escalation phase, based on PK data analysis from Cohorts 1 and 2, indicating CSF exposure levels of QRL-201 met or exceeded the targeted therapeutic range. The ANQUR clinical trial has advanced to the dose range-finding phase which will evaluate two doses of QRL-201 and include additional #biomarkers. The study design will now also include a cohort of participants with #C9orf72-related ALS in addition to participants with sporadic ALS. Based on previous expression analysis, patients with C9orf72-related ALS show consistent mis-splicing of STATHMIN-2 (#STMN2). QRL-201 is a first-in-class precision therapeutic product candidate that has the potential to restore STMN2 expression in ALS patients with the aim to modify disease progression and improve outcomes. The ANQUR clinical trial is currently active in Canada, the UK, and the EU. The first participant in the DRF phase has been dosed in Canada. #precisionmedicine #neurodegenerativediseases #neurologicaldiseases https://bit.ly/3YZ7S8F